LGR5 (Petosemtamab Biosimilar Antibody) 重組單克隆抗體是一種靶向人源LGR5蛋白，其別名包括FEX抗體、GPR49抗體、GPR67抗體、HG38抗體等，對(duì)應(yīng)靶點(diǎn)為富含亮氨酸重復(fù)序列G蛋白偶聯(lián)受體5（LGR5）。該抗體以重組人LGR5蛋白制備，具有高度的種屬特異性，僅對(duì)人源LGR5產(chǎn)生免疫反應(yīng)，為相關(guān)研究提供了精準(zhǔn)的靶向工具。 Petosemtamab Biosimilar Antibody作為靶向LGR5抗體，Petosemtamab類似物，被探索用于腫瘤靶向治療，通過(guò)特異性結(jié)合LGR5陽(yáng)性腫瘤細(xì)胞，發(fā)揮抑制腫瘤生長(zhǎng)或介導(dǎo)免疫殺傷的作用。目前，其其的研發(fā)聚焦于提高藥物可及性，為患者提供更經(jīng)濟(jì)的治療選擇，相關(guān)臨床試驗(yàn)正評(píng)估其在實(shí)體瘤治療中的安全性和有效性。 該抗體廣泛用于LGR5蛋白的檢測(cè)與功能研究，支持實(shí)驗(yàn)。研究人員借助它識(shí)別LGR5陽(yáng)性干細(xì)胞群體，探索干細(xì)胞在組織再生、腫瘤微環(huán)境中的作用機(jī)制，同時(shí)為L(zhǎng)GR5靶向藥物的篩選和療效評(píng)價(jià)提供基礎(chǔ)實(shí)驗(yàn)數(shù)據(jù)。其高特異性和種屬反應(yīng)性確保了實(shí)驗(yàn)結(jié)果的可靠性，推動(dòng)干細(xì)胞生物學(xué)與腫瘤學(xué)領(lǐng)域的機(jī)制研究。

P00533&O75473

EGFR&LGR5

FEX antibody; G protein coupled receptor 49 antibody; G protein coupled receptor 67 antibody; g protein-coupled receptor fex antibody; G-protein coupled receptor 49 antibody; G-protein coupled receptor 67 antibody; G-protein coupled receptor HG38 antibody; GPCR GPR49 antibody; GPR 49 antibody; GPR 67 antibody; GPR49 antibody; GPR67 antibody; GRP 49 antibody; GRP49 antibody; HG 38 antibody; HG38 antibody; Leucine rich repeat containing G protein coupled receptor 5 antibody; Leucine-rich repeat-containing G-protein coupled receptor 5 antibody; LGR 5 antibody; LGR5 antibody; LGR5_HUMAN antibody; MGC117008 antibody; Orphan G protein coupled receptor HG38 antibody

Human

Recombinant Human EGFR&LGR5 protein

Homo sapiens (Human)

Non-conjugated

Monoclonal

It differs from different batches. Please contact us to confirm it.

0.01M PBS，pH7.4

Liquid

Validation Status Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems. Guaranteed Quality ① Antibody purity?> 95% tested by SDS-PAGE. ② Endotoxin level < 0.1EU/ug tested by LAL method.

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

In stock

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.